ESTRO 2024 - Abstract Book

S934

Clinical - CNS

ESTRO 2024

2.PrACTiC: A Predictive Algorithm for Chemoradiotherapy-Induced Cytopenia in Glioblastoma Patients. Alireza Amouheidari , Zahra Alirezaei ,Stefan Rauh , and Masoud Hassanpour; Hindawi Journal of Oncology Volume 2022, Article ID 1438190, 7 pages https://doi.org/10.1155/2022/1438190

2641

Digital Poster

Stereotactic radiotherapy for breast cancer brain metastases: outcome and prognostic factors

Elena Clerici 1 , Pierina Navarria 1 , Luisa Bellu 1 , Ciro Franzese 1,2 , Davide Franceschini 1 , Ruggero Spoto 1 , Luca Dominici 1 , Federico Pessina 3,2 , Luciana Di Cristina 2,1 , Lorenzo Lo Faro 1 , Lucia Paganini 1 , Andrea Bresolin 1 , Pietro Mancosu 1 , Marta Scorsetti 1 1 IRCCS Humanitas Research Hospital, Radiotherapy and Radiosurgery, Rozzano, Italy. 2 Humanitas University, Biomedical Sciences, Pieve Emanuele, Italy. 3 IRCCS Humanitas Research Hospital, Neurosurgery, Rozzano, Italy

Purpose/Objective:

Breast cancer (BC) is the second most common cause of brain metastases (BMs). The incidence of brain metastases is increasing due to the longer overall survival related to modern systemic therapies (STs) and the greater use of MRI able to detect also small lesions. Despite availability of new STs, in cases of limited number and/or volume of BMs, local treatment remains the mainstay: radiosurgery (SRS) or hypofractionated radiosurgery (HSRS) exclusive or after surgery. We evaluated the clinical outcomes of a large series of BM-BC patients treated in our center using SRS, in terms of Local control (LC). Brain distant failure (BDF), progression-free survival (PFS) and overall survival (OS) were analyzed too.

Material/Methods:

For target definition and organs at risk delineation, post contrast T1MRI were acquired and basal CT scan was used for radiotherapy planning after coregistration. Different total doses and fractionation were delivered: 24 25Gy/1fraction, 20Gy/1fraction, 32Gy/4fractions, 30Gy/5fractions, according to tumor size and location, and 27 30Gy/3 fraction in cases of adjuvant HSRS after surgery

Results:

From October 2004 to August 2022, 169 patients, for a total of 504 BMs treated were evaluated. HER2 positive molecular profile represented the majority of patients (48%). Ninty (53%) of patients had one brain lesion and 48 (28%) underwent surgery before HSRS. After stereotactic radiotherapy, systemic treatment was administrated in 138. The median follow-up time was 24 months for the whole cohort and 54 months for alive patients. Median LC time was not reached, 1, 3 -year LC rates were 91.2%, and 79.5%, respectively. The median time, 1, 3year BDF were 15 months, 44.3%,76.8%. Median time, 1, 3 year PFS were 16 months, 53.6%,33.5%. Median time, 1, 3 year OS from radiotherapy were 39 months, 74.8%, 51.8%, and it improved by the starting a ST after the BM treatment at both